Scientifically based combination therapies with immuno‐oncology checkpoint inhibitors
The discovery of immune checkpoints and their role in modulating immune response have revolutionised cancer treatment in recent years. The immune checkpoints, cytotoxic T‐lymphocyte‐associated protein 4, programmed cell death protein 1 and its ligand, programmed cell death‐ligand 1, have been extensively studied. Currently 7 monoclonal antibodies targeting these immune checkpoints are approved for treatment of various cancers. Inhibiting immune checkpoints has shown some success in clinic, however, a proportion of patients do not benefit from this treatment. Several other inhibitory molecules, in addition to lymphocyte‐associated protein 4 and programmed cell death protein 1, are known to be involved in regulating immune response. To further improve patient outcomes, studies have examined targeting these inhibitory molecules through combination therapies. This review discusses the current landscape of combination therapies of checkpoint inhibitors..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:86 |
|---|---|
| Enthalten in: |
British Journal of Clinical Pharmacology - 86(2020), 9, Seite 1711-1725 |
| Beteiligte Personen: |
Chew, Hui Yi [VerfasserIn] |
|---|
| BKL: |
|---|
| Anmerkungen: |
© 2020 The British Pharmacological Society |
|---|
| Umfang: |
15 |
|---|
| doi: |
10.1111/bcp.14338 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
WLY002622610 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | WLY002622610 | ||
| 003 | DE-627 | ||
| 005 | 20230307120812.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230213s2020 xx |||||o 00| ||und c | ||
| 024 | 7 | |a 10.1111/bcp.14338 |2 doi | |
| 028 | 5 | 2 | |a BCP_BCP14338.xml |
| 035 | |a (DE-627)WLY002622610 | ||
| 035 | |a (WILEY)BCP14338 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 082 | 0 | 4 | |a 610 |q ASE |
| 084 | |a 44.38 |2 bkl | ||
| 084 | |a 44.40 |2 bkl | ||
| 100 | 1 | |a Chew, Hui Yi |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Scientifically based combination therapies with immuno‐oncology checkpoint inhibitors |
| 264 | 1 | |c 2020 | |
| 300 | |a 15 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © 2020 The British Pharmacological Society | ||
| 520 | |a The discovery of immune checkpoints and their role in modulating immune response have revolutionised cancer treatment in recent years. The immune checkpoints, cytotoxic T‐lymphocyte‐associated protein 4, programmed cell death protein 1 and its ligand, programmed cell death‐ligand 1, have been extensively studied. Currently 7 monoclonal antibodies targeting these immune checkpoints are approved for treatment of various cancers. Inhibiting immune checkpoints has shown some success in clinic, however, a proportion of patients do not benefit from this treatment. Several other inhibitory molecules, in addition to lymphocyte‐associated protein 4 and programmed cell death protein 1, are known to be involved in regulating immune response. To further improve patient outcomes, studies have examined targeting these inhibitory molecules through combination therapies. This review discusses the current landscape of combination therapies of checkpoint inhibitors. | ||
| 700 | 1 | |a Dolcetti, Riccardo |4 aut | |
| 700 | 1 | |a Simpson, Fiona |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t British Journal of Clinical Pharmacology |g 86(2020), 9, Seite 1711-1725 |w (DE-627)WLY00261751X |x 13652125 |7 nnns |
| 773 | 1 | 8 | |g volume:86 |g year:2020 |g number:9 |g pages:1711-1725 |g extent:15 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_WLY | ||
| 912 | |a SSG-OPC-PHA | ||
| 912 | |a SSG-OPC-ASE | ||
| 936 | b | k | |a 44.38 |q ASE |
| 936 | b | k | |a 44.40 |q ASE |
| 951 | |a AR | ||
| 952 | |d 86 |j 2020 |e 9 |h 1711-1725 |g 15 | ||